FeesSafety
Pluang+
Trading Halt
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Allakos Inc (ALLK) Stock Price Today

24H
1W
1M
3M
YTD
1Y
5Y

French firms boost AI-driven cybersecurity, focusing on productivity and operational results over processes.

A new study by Securonix shows French organizations are increasingly adopting AI-driven cybersecurity operations, prioritizing productivity and measurable outcomes rather than just processes. French firms lead in allowing AI to automatically trigger ...

Market News
1 hour ago
Securonix
Neutral
French firms boost AI-driven cybersecurity, focusing on productivity and operational results over processes.

Exosens secures a major order for 25,000 light intensifier tubes for night vision devices through 2030.

Exosens has received a firm order for 25,000 high-performance 4G+ light intensifier tubes to equip night vision products for Theon, under a long-term supply agreement extended through 2030. The order includes options for an additional 35,000 tubes, p...

Market News
3 hours ago
Na
Bullish
news icon
Exosens secures a major order for 25,000 light intensifier tubes for night vision devices through 2030.

Exosens wins order for 25,000 image intensifier tubes to boost European night vision tech.

Exosens secured a firm order to supply 25,000 high-performance 4G+ image intensifier tubes to Theon Sensors for integration into night vision devices, with deliveries starting late 2026. This order is part of a long-term agreement through 2030 and in...

Market News
3 hours ago
Na
Bullish
news icon
Exosens wins order for 25,000 image intensifier tubes to boost European night vision tech.

FDA updates MYQORZO label with Phase 3 data showing it outperforms beta-blocker metoprolol in treating oHCM.

Cytokinetics announced FDA approval to update MYQORZO's prescribing information to include Phase 3 MAPLE-HCM trial data comparing MYQORZO (aficamten) to the beta-blocker metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy (o...

Market News
5 hours ago
GlobeNewsWire
Bullish
news icon
FDA updates MYQORZO label with Phase 3 data showing it outperforms beta-blocker metoprolol in treating oHCM.

VirTra names Caleb Rauch as new Director of Operations to boost manufacturing and growth.

VirTra, a global provider of use-of-force and firearms training simulators, appointed Caleb Rauch as Director of Operations effective November 16, 2026. Rauch brings over 15 years of manufacturing and operations experience, notably in aerospace compo...

Market News
5 hours ago
GlobeNewsWire
Bullish
news icon
VirTra names Caleb Rauch as new Director of Operations to boost manufacturing and growth.

Beer tops Brits' drink choices, with no and low-alcohol options growing in popularity.

New research by Budweiser Brewing Group shows beer is the most popular alcoholic drink among Brits, preferred by 30% over wine and spirits. No and low-alcohol beer options are also leading the moderation trend, chosen by 18.5% of respondents, nearly ...

Market News
5 hours ago
GlobeNewsWire
Bullish
news icon
Beer tops Brits' drink choices, with no and low-alcohol options growing in popularity.

Aclaris starts Phase 2b trial of modzatinib for lichen planus, aiming for first oral therapy with FDA Fast Track status.

Aclaris Therapeutics has initiated a Phase 2b clinical trial for modzatinib (ATI-2138), targeting moderate-to-severe lichen planus (LP), a chronic inflammatory disease with no approved treatments. Modzatinib uniquely inhibits ITK and JAK3 pathways, p...

Market News
5 hours ago
GlobeNewsWire
Bullish
news icon
Aclaris starts Phase 2b trial of modzatinib for lichen planus, aiming for first oral therapy with FDA Fast Track status.

Iovance's revenue jumps 77% but lung cancer trial results drag stock down 48%

Iovance Biotherapeutics reported a strong quarter with Amtagvi revenue up 77% to $101.6 million and nearly halted cash burn at -$4.47 million. However, disappointing lung cancer trial results caused the stock to drop 47.6% since October 28, as the re...

Market News
5 hours ago
Seeking Alpha
Bullish
news icon
Iovance's revenue jumps 77% but lung cancer trial results drag stock down 48%

Riverside and Questcorp start Phase 2B drilling at La Union gold project in Sonora, Mexico

Riverside Resources and Questcorp Mining have begun Phase 2B of their reverse circulation drilling program at the La Union Project in Sonora, Mexico. The program targets gold mineralization at Luis Hill and the Union Mine, testing new geophysical ano...

Market News
6 hours ago
GlobeNewsWire
Bullish
news icon
Riverside and Questcorp start Phase 2B drilling at La Union gold project in Sonora, Mexico

Harrow Inc. nears $350M 2026 revenue goal after strong Q3 growth and expanded sales efforts.

Harrow Inc., a Nashville-based ophthalmology company, showed strong Q3 performance with significant quarter-over-quarter growth in its products VEVYE (up 35%) and IHEEZO (up 62%). The company is expanding its commercial coverage and sales team, which...

Market News
6 hours ago
Seeking Alpha
Bullish
news icon
Harrow Inc. nears $350M 2026 revenue goal after strong Q3 growth and expanded sales efforts.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

Key Stats

  • Market Cap
    $29.74M
  • Volume
    -
  • Sector
    Health
  • 52W High
    $1.50
  • 52W Low
    $0.22
  • Typical Hold Time
    37 Days
  • Enterprise Value
    -$46.92M
  • Div Yield
    -
  • Trading Activity
    -
$0.33
52W Low: $0.22
01 Apr 2025
52W High: $1.5
11 Nov 2024

Track Allakos Inc (ALLK) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Allakos Inc has traded between a low of $0.22 and a high of $1.5, highlighting its annual price range. Buy and sell Allakos Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!